Becton, Dickinson and Company (BDX) स्टॉक विश्लेषण

कंपनी का अवलोकन

Becton, Dickinson and Company functions as a comprehensive provider of medical supplies, devices, laboratory equipment, and diagnostic products serving healthcare institutions, physicians, life science researchers, and clinical laboratories globally. The enterprise operates within the Healthcare sector, specifically the Medical Instruments & Supplies industry, which implies a focus on essential equipment required for patient care and medical research rather than pharmaceutical drug development. This entity commands a substantial market capitalization of $56.32 billion, supported by an annual revenue of $21.92 billion and a workforce comprising 70,000 employees. These valuation and revenue figures indicate that the company holds a significant position within the global medical device market, reflecting a large-scale operation with deep market penetration and established distribution networks across diverse healthcare segments.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $21.92 billion, generating a net income of $1.76 billion and an EBITDA of $6.04 billion. The substantial gap between the $21.92 billion in revenue and the $1.76 billion in net income reveals a significant cost structure, where operating expenses, including cost of goods sold, research and development, and administrative costs, consume approximately 92% of total sales before accounting for interest and taxes. Free cash flow stands at $3.11 billion, which provides the organization with considerable financial flexibility to fund capital expenditures, pursue strategic acquisitions, or return capital to shareholders without compromising operational liquidity. The company maintains a gross margin of 46.8%, indicating strong pricing power and efficient manufacturing capabilities in its product lines. An operating margin of 13.3% suggests effective control over overhead costs and operational efficiency relative to revenue generation. The profit margin of 8.0% reflects the final profitability after all expenses, interest, and taxes have been deducted, showing the company's ability to convert sales into actual earnings. Regarding liquidity and leverage, the firm holds $751.00 million in cash against total debt of $19.54 billion, resulting in a debt-to-equity ratio of 77.28, which suggests a leveraged balance sheet typical for capital-intensive industries. The current ratio is 1.05, indicating that the company's current assets are slightly higher than its current liabilities, pointing to a tight but manageable short-term liquidity position. Return on equity is 7.0% and return on assets is 4.1%, metrics that reveal the effectiveness of management in utilizing shareholder equity and total assets to generate profits, though these returns are moderate compared to high-growth technology sectors.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is 25.36, while the forward P/E is 11.51, implying that the market expects a significant acceleration in earnings growth that would justify a lower multiple in the future. The price-to-book ratio of 1.75 indicates that the stock trades at a premium of 75% above its book value, reflecting investor confidence in the company's intangible assets and future earnings potential beyond its tangible asset base. Alternative valuation metrics such as a price-to-sales ratio of 2.57 and an EV/EBITDA of 10.44 suggest that the company is valued reasonably relative to its sales volume and cash-generating ability before interest, taxes, depreciation, and amortization. The 52-week high is $187.35 and the 52-week low is $127.59, establishing a trading range where the current market price must be contextualized against these bounds to assess relative strength or weakness. The beta value is 0.35, which signifies that the stock exhibits low volatility and tends to move less than the broader market, offering a degree of stability for risk-averse portfolios.

Growth & Income

Revenue growth year-over-year is 1.6%, while earnings growth year-over-year is 28.6%, demonstrating that earnings are expanding significantly faster than revenue, which often implies improving operating leverage or favorable pricing adjustments. As a dividend payer, the company offers a dividend yield of 2.7% with a payout ratio of 68.1%, indicating that the dividend is funded by a substantial portion of net income, which must be monitored closely to ensure sustainability given the moderate return on equity. The elevated earnings growth relative to revenue suggests that the business model is becoming more efficient or that high-margin product mix shifts are occurring, allowing for robust profit expansion even with modest top-line increases. Overall, the company presents a profile characterized by steady revenue expansion, accelerating earnings, and a consistent commitment to dividend distribution alongside a relatively low-beta market exposure.